All In Biotech

Drug Trial Radar · NCT01605136

Phase III Confirmatory Study in Erythropoietic Protoporphyria

A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)

Last checked: Nov 20, 2026Latest source record: Sep 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

93

Actual

Start

May 2012

Primary completion

Jul 2013

Study completion Jul 2013

Sponsor

Sponsor type
Industry
First posted
May 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized placebo-controlled study to be conducted in two parallel study arms for a six month period (three doses). Between 75 and 100 eligible patients will be enrolled. Patients will receive afamelanotide (16 mg implants) or placebo according to the following dosing regimen: * Group A will be administered afamelanotide implants on Days 0, 60 and 120 * Group B will be administered placebo implants on Days 0, 60 and 120 The number and severity of phototoxic reactions, the type and duration of sun exposure, treatment-emergent adverse events and the use of concomitant medication will be recorded by patients in study diaries between Days 0 and 180. Quality of life will be measured using the DLQI and EPP-QoL at Days 0, 60, 120 and 180. Participants will visit the clinic on Days 60, 120 and 180 for assessments of adverse events. A subset of patients will be photoprovoked on the lower back and dorsal surface of the hand and the minimal symptom dose (MSD) will be determined on Days 0, 30, 60, 90 and 120.

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • AfamelanotideDrug

    One 16mg subcutaneous implant every 2 months for 6 months.

  • PlaceboDrug

    One placebo subcutaneous implant every 2 months for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Direct Sunlight Exposure Between 10:00 and 18:00 Hours on Days When no Pain Was Experienced (Pain Score of 0).Time frame: Daily for 6 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • University of California, San Francisco

    San Francisco, California

  • Henry Ford Medical Center

    Detroit, Michigan

  • Mt. Sinai

    New York, New York

  • Carolina's Medical Center Cannon Research

    Charlotte, North Carolina

  • University of Texas

    Galveston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.